Final Recommendation Statement
Unhealthy Drug Use: Screening
June 09, 2020
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
|Table of Contents|
Many people in the US experience problems related to unhealthy drug use, defined in this recommendation statement as the use of illegal drugs and the nonmedical use of prescription psychoactive medications (ie, use of medications for reasons, for duration, in amounts, or with frequency other than prescribed or use by persons other than the prescribed individual). In 2018, an estimated 12% of US residents 18 years or older reported current unhealthy drug use in a national survey.1 Unhealthy drug use is more commonly reported by young adults aged 18 to 25 years (24%) than by older adults (10%) or adolescents aged 12 to 17 years (8%). In 2018, an estimated 5.4% of pregnant persons aged 15 to 44 years reported unhealthy drug use in the last month. Adults 18 years or older (10.5%) and adolescents aged 12 to 17 years (8.0%) more commonly reported cannabis use in the last month than nonmedical use of psychotherapeutic medications, including pain relievers (2.1% and 1.3%, respectively) and opioids (1.2% and 0.7%, respectively).1 In both age groups, less than 1% reported use of heroin, cocaine, hallucinogens, inhalants, or methamphetamines in the last month.
An estimated 8 million persons 12 years or older met diagnostic criteria for drug dependence or abuse of drugs in the past year.1 Drug use is one of the most common causes of preventable death, injuries, and disability.2,3 In 2017, unhealthy drug use caused more than 70,000 fatal overdoses.4 Drug use can cause many serious health effects that vary by drug type, administration mode, amount, and frequency of use, as well as pregnancy status.5 Opioid use can cause drowsiness, slowed breathing, constipation, coma, and fatal overdose. Stimulants such as cocaine can cause arrhythmias, myocardial infarction, seizures, and other complications. Marijuana use is associated with slowed reaction time; problems with balance, coordination, learning, and memory; and chronic cough and frequent respiratory infections.5 Injection drug use may result in blood-borne viral and bacterial infections.2,5 Drug use during pregnancy can increase risk of obstetric complications such as placental abruption, preeclampsia, and third trimester bleeding, as well as adverse fetal and infant outcomes such as spontaneous abortion, abnormal brain growth, preterm delivery, low birth weight, and neonatal abstinence syndrome.6 Drug use is also associated with violence, criminal activity, incarceration, impaired school and work performance, interpersonal dysfunction, and other social and legal problems.7
Adults 18 Years or Older
The USPSTF concludes with moderate certainty that screening by asking questions about unhealthy drug use in adults has moderate net benefit when services for accurate diagnosis of unhealthy drug use or drug use disorders, effective treatment, and appropriate care can be offered or referred.
Adolescents Aged 12 to 17 Years
Because of the lack of evidence, the USPSTF concludes that the benefits and harms of screening for any type of unhealthy drug use in adolescents are uncertain and that the balance of benefits and harms cannot be determined.
See the Table for more information on the USPSTF recommendation rationale and assessment. For more details on the methods the USPSTF uses to determine the net benefit, see the USPSTF Procedure Manual.8
Patient Population Under Consideration
This recommendation statement applies to adults 18 years or older, including pregnant and postpartum persons, and adolescents aged 12 to 17 years in primary care settings. This statement does not apply to adolescents or adults who have a currently diagnosed drug use disorder or are currently undergoing or have been referred for drug use treatment. This statement applies to settings and populations for which services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. The net benefit assessment does not apply to settings and populations for which treatment cannot be provided or the result of screening is punitive.
For the purposes of this recommendation, “unhealthy drug use” is defined as the use of substances (not including alcohol or tobacco products) that are illegally obtained or the nonmedical use of prescription psychoactive medications; that is, use of medications for reasons, for duration, in amounts, or with frequency other than prescribed or by persons other than the prescribed individual. These substances are ingested, inhaled, injected, or administered using other methods to affect cognition, affect, or other mental processes; to “get high”; or for other nonmedical reasons. Unhealthy drug use is abbreviated as “drug use” in this recommendation statement.
Screening refers to asking 1 or more questions about drug use or drug-related risks in face-to-face, print, or audiovisual format. It does not refer to testing urine, saliva, blood, or other biological specimens for the presence of drugs.
Assessment of Risk
The USPSTF recommends screening by asking questions in all adults 18 years or older regardless of risk factors for unhealthy drug use. However, some factors are associated with a higher prevalence of unhealthy drug use. These include being aged 18 to 25 years; male sex; having a mental health condition, personality or mood disorder, or nicotine or alcohol dependence; a history of physical or sexual abuse, parental neglect, or other adversity in childhood; or drug or alcohol addiction in a first-degree relative.1,9 Factors associated with misuse of prescription drugs include history of other drug use, mental illness, pain, and greater access to prescription drugs.10 Factors associated with prenatal use of drugs include a mental health disorder, interpersonal violence, and family history of substance use.11
Several screening tools that ask questions about drug use are available for identifying 1 or more classes of unhealthy drug use, the frequency or severity of use, or drug-related health, social, or legal consequences that characterize unhealthy use or drug use disorders. Interviewer-administered tools and self-administered tools appear to have similar accuracy.12
Primary care practices may consider several factors when selecting screening tools. Brief tools (eg, NIDA [National Institute on Drug Abuse] Quick Screen, which asks 4 questions about use of alcohol, tobacco, nonmedical use of prescription drugs, and illegal drugs in the past year) may be more feasible in busy primary care settings, but longer tools (eg, the 8-item ASSIST [Alcohol, Smoking and Substance Involvement Screening Test]) that assess risks associated with unhealthy drug use or comorbid conditions may reveal information signaling the need for prompt diagnostic assessment. Tools with questions about nonmedical use of prescription drugs (eg, TAPS [Tobacco, Alcohol, Prescription Medication, and Other Substance Use]) may be useful when clinicians are concerned about prescription misuse. One study reported that drug use questions in the PRO (Prenatal Risk Overview) risk assessment tool were reasonably accurate for identifying drug abuse or dependence in pregnant women.
Screening tools are not meant to diagnose drug dependence, abuse, addiction, or drug use disorders. Patients with positive screening results may, therefore, need to be offered or referred for diagnostic assessment.
There is little evidence about the optimal time to start asking about unhealthy drug use or the optimal interval for screening in adults older than 18 years.
Treatment of drug use disorders is based on the type of drug used, the severity of drug use, and the type of use disorder. Many drug use disorders are chronic, relapsing conditions, and many persons who start treatment do not complete treatment.13 Therefore, treatment must often be repeated to stabilize current drug use, reduce relapse, and achieve abstinence or other treatment goals. Some patients, such as those who are pregnant, nursing, or caring for ill or healthy neonates, may require specialized treatment settings.
Pharmacotherapy, which is often provided with individual or group counseling, is the standard for treatment of opioid use disorders involving heroin or prescription opioid use in adults and pregnant and postpartum persons.14-16 Drug use disorders involving nonopioid drugs, such as cannabis, stimulants, and some prescription drugs, are generally treated with various psychosocial interventions that usually involve multiple sessions of cognitive behavioral therapy, motivational interventions, contingency management, relapse prevention, community reinforcement, family behavioral therapy, 12-step facilitation therapy, or other behavioral approaches. Intensive interventions usually involve several in-person sessions over several weeks or months.
The management of patients who screen positive is usually accompanied by other interventions, including testing for blood-borne pathogens; assessment of misuse of, abuse of, or dependence on alcohol or tobacco; assessment of potentially coexisting mental health disorders; and pain management for patients with pain who are abusing opioids.
In practice, the benefits and harms of screening may vary because of several health, social, and legal issues. In many communities, affordable, accessible, and timely services for diagnostic assessment and treatment of patients with positive screening results are in limited supply or unaffordable.
To minimize the potential adverse effects such as stigma, labeling, or medicolegal consequences of asking questions about drug use and documenting and reporting answers, clinicians should be aware of state requirements and best practices on informed consent for screening, mandatory screening, documenting screening results in medical records, reporting of screening results to medicolegal authorities, and confidentiality protections (see the Additional Tools and Resources section).17-24 This recommendation statement applies to settings and populations for which services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. The net benefit assessment does not apply to settings and populations for which treatment is not provided or the result of screening is punitive.
Additional Tools and Resources
Several tools may help clinicians implement this screening recommendation (Box).
Suggestions for Practice Regarding the I Statement for Adolescents Aged 12 to 17 Years
Potential Preventable Burden
Based on a national survey in 2018, 8% of adolescents aged 12 to 17 years reported drug use in the last month. Among youth reporting such drug use, the most commonly used substances were marijuana, inhalants, prescription psychotherapeutic drugs, opioids, and hallucinogens.1 An estimated 2.7% met diagnostic criteria for drug dependence or abuse,1 and the vast majority presented with concurrent mental health diagnoses.25 Risk factors for drug use in youth include aggressive childhood behavior, lack of parental supervision, poor social skills, access to drugs at school, and community poverty.26
Adolescent substance use, including use of heroin and misuse of prescription opioids, is associated with the leading causes of death—suicide, overdose, unintentional injury, and violence in adolescents and young adulthood.25 Substance use during this period of rapid brain development can also harm neurocognitive development and endocrine function that, in turn, can impair academic, occupational, and social functioning.26-28 Adolescents with drug use disorders are also at increased risk of sexually transmitted infections, other physical health problems, unintended pregnancies, criminal involvement, and school truancy.25
Potential Harms of Screening and Treatment
Although there is limited evidence on harms, adolescents may experience potential harms from screening for drug use such as labeling and stigmatization. Because of concerns about long-term use of opioid agonists, the US Food and Drug Administration (FDA) restricts approval for buprenorphine to youth 16 years or older, and the US Department of Health and Human Services restricts admission to methadone programs to youth younger than 18 years who continue to use opioids after at least 2 rounds of detoxification and psychosocial interventions.28
About 50% to 86% of pediatricians report routinely screening for substance use, and most screen using their clinical impressions rather than a validated screening tool.22
Other Related USPSTF Recommendations
The USPSTF has issued recommendation statements on these related topics:
- Interventions to prevent drug use in children, adolescents, and young adults29
- Screening and behavioral counseling interventions for reducing unhealthy alcohol use in adolescents and adults30
- Interventions for tobacco smoking cessation in adults, including pregnant women31
- Primary care interventions to prevent tobacco use in children and adolescents32
- Screening for depression in adults33
- Screening for depression in children and adolescents34
This recommendation statement replaces the 2008 USPSTF recommendation, which concluded that the evidence at that time was insufficient to assess the balance of benefits and harms of screening for illicit drug use in adolescents and adults, including those who were pregnant or postpartum.36 This updated statement incorporates new evidence since 2008 about the accuracy of screening tools and the benefits and harms of treatment of unhealthy drug use or drug use disorders. This new evidence supports the current recommendation that primary care clinicians offer screening to adults 18 years or older, including those who are pregnant or postpartum, when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. The USPSTF continues to conclude that the evidence is insufficient to assess the balance of benefits and harms of screening for drug use in adolescents.
Scope of Review
The USPSTF commissioned 2 systematic evidence reviews in support of this updated recommendation statement. These reviews evaluated evidence on the benefits and harms of screening for drug use, accuracy of screening tools to detect drug use, and the benefits and harms of psychosocial interventions and pharmacotherapy.12,37,38
Accuracy of Screening Tools
The USPSTF identified 30 different screening tools that were evaluated in adults, pregnant or postpartum persons, or adolescents. Many tools had sensitivity of 75% or more for detecting unhealthy drug use, drug abuse or dependence, or drug use disorders. Most screening studies used structured clinical or diagnostic interviews that used varying definitions of drug use, abuse, dependence, and drug use disorders as the reference standard. Few studies used biologic reference standards such as testing of hair or urine specimens.12,37
The USPSTF reviewed 12 studies that assessed the accuracy of 15 different screening tools in nonpregnant adults.12,37 There was considerable variation in sample size (139 to 2057, not including a large US-based national sample of 42,923), proportion of female participants (4.7% to 94%), and mean age (25.2 to 62.6 years). All but 2 studies were conducted in the US. The use and severity of use of any drug or specific drugs varied widely across study populations. The prevalence of unhealthy use of any drug ranged from 14.2% to 37.9% and the prevalence of use disorders due to any drug ranged from 1.8% to 16.7%, based on reference standards of clinical interviews (with or without confirmation of drug use by saliva testing).
Several screening tools directly addressed the frequency of drug use (single-item drug frequency; SUBS [Substance Use Brief Screen]; and TAPS-1) or the frequency of drug use and risks associated with drug use (ASSIST; ASSIST-Drug; CAST [Cannabis Abuse Screening Test]; 2-, 10-, and 28-DAST [Drug-Abuse Screening Test]; PDUQp [Prescription Drug Use Questionnaire-Patient Version]; PSQ [Parent Screening Questionnaire]; SoDU [Screen of Drug Use]; TAPS; and TICS [Two-Item Conjoint Screen], all of which are examples of “direct tools”). One tool indirectly assessed drug use by asking questions about alcohol or tobacco use (single-item heavy episode drinking frequency [an example of an “indirect tool”]).12
The sensitivity of direct tools for detecting unhealthy use of “any drug” (including illegal drugs and nonmedical use of prescription drugs) in the past month or year ranged from 0.71 to 0.94 (95% CI, 0.62-0.97), and specificity ranged from 0.87 to 0.97 (95% CI, 0.83-0.98). Direct tool sensitivity for detecting abuse or dependence or a use disorder related to “any drug” ranged from 0.85 to 1.00 (95% CI, 0.75-1.00) and specificity ranged from 0.67 to 0.93 (95% CI, 0.58-0.95). Screening tools had higher sensitivity for detecting unhealthy drug use and drug use disorders related to “any drug” (most of which was cannabis), cannabis, heroin, and stimulants than for detecting unhealthy drug use or drug use disorders related to nonmedical use of prescription drugs, including opioids or sedatives (range, 0.38-0.96 [95% CI, 0.29-0.99]) but specificity was comparable (range, 0.79-1.00 [95% CI, 0.71-1.00]).12
Four studies assessed the accuracy of direct tools (the frequency-based ASSIST-2 tool and the risk assessment–based DAST-10, PRO, and WIDUS [Wayne Indirect Drug Use Screener]/ASSIST-2 [modified tool]) or an indirect tool (WIDUS) for detecting drug use or drug use disorders (not including alcohol) in women recruited during prenatal care visits or shortly after delivery. The prevalence of any prenatal drug use varied from 1.2% to 41% across these 4 studies. Sensitivity for detecting any prenatal use of drugs using direct tools ranged from 0.37 to 0.76 (95% CI, 0.24-0.86) and specificity ranged from 0.68 to 0.83 (95% CI, 0.55-0.91). One study of the PRO risk assessment–based tool (in a population in which 7% met diagnostic criteria for drug abuse, dependence, or both) reported sensitivity for detecting any drug abuse or dependence of 0.89 (95% CI, 0.77-0.95) and specificity of 0.74 (95% CI, 0.71-0.77). The only indirect tool that reported on any prenatal use of drugs, not including alcohol (WIDUS/ASSIST-2), had lower sensitivity (0.68 [95% CI, 0.53-0.80]) and specificity (0.69 [95% CI, 0.57-0.80]). An additional study of the indirect tool Parents Partner Past Pregnancy reported high sensitivity (0.87 [95% CI, 0.71-0.95) and high specificity (0.76 [95% CI, 0.70-0.82]) for detecting the combined outcome of any prenatal use of drugs or alcohol but did not assess the outcome of prenatal use of drugs alone.12
The evidence on accuracy of screening tools in adolescents is limited. Most studies focus on the detection of cannabis use; no studies provide information specifically on opioid use or other drug classes. Few tools that assess cannabis use were evaluated in more than 1 study. The available studies evaluated direct tools—the Brief Screener for Tobacco, Alcohol, and Other Drugs; a single item assessing cannabis use; ASSIST; ASSIST-Lite; CAST; CPQ-A-S (Cannabis Problems Questionnaire for Adolescents-Shortened); CRAFFT (Car Relax Alone Forget Family/Friends Trouble); PESQ-PS (Personal Experience Screening Questionnaire-Problem Severity Scale); POSIT (Problem Oriented Screening Instrument for Teenagers); and SDS (Severity Dependence Scale)—against a diagnostic interview. Sensitivity of these direct tools for detecting any cannabis use or unhealthy use ranged from 0.68 to 0.98 (95% CI, 0.64-0.99) and specificity ranged from 0.82 to 1.00 (95% CI, 0.80-1.00). Sensitivity of these direct tools for detecting cannabis use disorders ranged from 0.71 to 0.98 (95% CI, 0.41-1.00) and specificity ranged from 0.79 to 0.95 (95% CI, 0.77-0.98). Given the limited number of studies on individual tools and the lack of information on the accuracy of tools for detecting use of drugs other than cannabis, the USPSTF determined the evidence on accuracy of screening in adolescents to be inadequate.12
Benefits of Screening and Treatment
No studies directly addressed the benefits of screening on reducing drug use or drug-related health, social, or legal outcomes in adults or adolescents.
Several trials found that use of FDA-approved pharmacotherapy had benefits for nonpregnant adults with opioid use disorders who had sought or were referred for treatment for symptoms, signs, or drug-related health, social, or legal problems (hereafter abbreviated as “treatment-seeking populations”). Adults assigned to pharmacotherapy generally had lower rates of relapse and increased retention in treatment than adults assigned to placebo or no treatment.37,38
Nineteen trials evaluated naltrexone (opioid antagonist), buprenorphine (partial opioid agonist), or methadone (opioid agonist) (usually provided with individual or group counseling) in adults with opioid use disorder primarily related to heroin. None assessed the effects of pharmacotherapy in adults whose opioid use disorder was related only to prescription opioids or was detected through primary care screening. Trials recruited participants from inpatient settings, drug treatment programs, and criminal justice systems. Most trials were conducted outside the US, and several used naltrexone formulations not available in the US. Most participants were adult males younger than 30 years. No trials specifically enrolled pregnant or postpartum persons or adolescents, although FDA-approved pharmacotherapy agents are available for these patient populations. However, women of reproductive age comprised 25% to 46% of trial participants who received methadone or buprenorphine and 0% to 28% of participants who received naltrexone.37,38
Thirteen trials evaluated the effects of oral, injectable, or implantable naltrexone. Outcomes were assessed during the course of treatment in 11 trials (2-9 months after start of treatment) or after treatment completion in 2 trials (6-10 months after completion). Sample sizes ranged from 31 to 306 (total N?=?1718 participants). Retention in treatment varied considerably in persons assigned to naltrexone (range, 7%-60%) and persons assigned to placebo or no treatment (range, 6%-56%). Use of naltrexone was associated with a significant decrease in drug use relapse (pooled relative risk [RR], 0.73 [95% CI, 0.62-0.85]) and increased retention in treatment (pooled RR, 1.71 [95% CI, 1.13-2.49]). The few naltrexone trials that reported on mortality, global functioning, quality of life, anxiety, depression, or legal or employment outcomes had inconsistent findings regarding these outcomes, but mortality was rare.37,38
Seven trials assessed the opioid agonist methadone, the partial opioid agonist buprenorphine, or both. During the course of ongoing treatment with 1 of these 2 opioid agonists (monitored for 4-12 months), use of methadone and sublingual or implantable buprenorphine was significantly associated with a decrease in relapse (4 trials; pooled RR, 0.75 [95% CI, 0.59-0.82]) and increased retention in treatment (7 trials; pooled RR, 2.58 [95% CI, 1.78-4.59]). Findings from 5 trials that assessed the effects of opioid agonists on health, social, and legal outcomes were mixed and did not show clear treatment benefits. A few trials found that buprenorphine was associated with better self-reported scores on quality of life, well-being, and life satisfaction. No deaths were reported in trials that reported this outcome.37,38
Adults. Psychosocial interventions were associated with increased likelihood of abstaining from use of drugs vs control conditions at 3 to 4 months (15 trials; RR, 1.60 [95% CI, 1.24-2.13]) and at 6 to 12 months (14 trials; RR, 1.25 [95% CI, 1.11-1.52]).37,38
Approximately one-half of the psychosocial intervention trials enrolled persons who had sought or were referred for drug treatment. Sample sizes ranged from 34 to 1175 (total N?=?15,659). Most trials were conducted in the US and included participants who were primarily male, nonwhite, and had lower socioeconomic status. The severity of drug use in trial participants varied greatly. Interventions were categorized as intensive (defined as more than 2 sessions or 2 sessions lasting more than 1 hour each) or brief (defined as 1 to 2 sessions each lasting 1 hour or less). Interventions were generally based on established behavioral approaches and were administered by telephone or in person by researchers or were self-administered by computer. Intensive interventions commonly used face-to-face cognitive behavioral therapy, motivational interviewing, and contingency management approaches. Most brief interventions consisted of a single, personalized counseling session with in-person or computer-based feedback, with or without a telephone or in-person booster session. Follow-up ranged from 3 to 4 months to 12 or more months after the start of interventions. Thirty-eight percent to 98% of participants completed assessments at designated follow-up points. Meta-analyses and sensitivity analyses included only the subset of trials with data that could be pooled and combined trials that evaluated nonpregnant adults, pregnant or postpartum adults, or adolescents; any type of drug use; and either brief or intensive interventions.38
In sensitivity analyses, effects on abstinence were greater at 3 to 4 months in trials of treatment-seeking populations (7 trials; RR, 2.08 [95% CI, 1.51-3.07]) than in trials of screen-detected populations (8 trials; RR, 1.28 [95% CI, 0.97-1.84]; P?=0.05 for interaction). Effects on abstinence were smaller in trials of brief interventions than in trials of intensive interventions, but the differences were not statistically significant. Effects were statistically significant for abstinence from cannabis use (7 trials; RR, 2.08 [95% CI, 1.51-3.07] at 3 to 4 months and 4 trials; RR, 1.58 [95% CI, 1.17-3.06] at 6 to 12 months), but not for abstinence from stimulants or mixed drug use. Results of meta-analyses on the association of psychosocial interventions and other outcomes, including number of days using drugs and drug use severity, were mixed. Evidence on the association between psychosocial interventions and health, social, or legal outcomes related to use of cannabis, stimulants, opioids, “any drug,” or mixed drugs in adults was sparse and showed no or limited effectiveness.38
Five trials specifically assessed intensive or brief interventions exclusively in pregnant or postpartum persons compared with attention control groups or information and advice from obstetricians or nurses. None reported significant effects on drug use or health, social, or legal outcomes of drug use at 3 to 6 months after the start of the interventions.12
Adolescents. There were few trials on psychosocial interventions that focused on adolescents aged 12 to 17 years. Evidence was limited and results were inconclusive.12,38 These studies did not report the effect of psychosocial interventions on drugs other than cannabis.
Harms of Screening and Treatment
No studies addressed the harms of screening in adults or adolescents.12
Eleven naltrexone trials and 4 buprenorphine trials assessed potential harms, including suicide, overdose, or study withdrawal due to serious adverse events, but no methadone trials assessed harms. Few harms or serious adverse events were reported. In pooled analyses, the risk of adverse events was generally similar in persons assigned to pharmacotherapy and control groups, including the risk of study discontinuation due to adverse events (3 trials; RR, 1.54 [95% CI, 0.35-8.31]) or serious adverse events (3 trials; RR, 1.24 [95% CI, 0.11-10.21]) in trials of naltrexone or the risk of serious adverse events (2 trials; RR, 0.32 [95% CI, 0.09-1.12]) in trials of buprenorphine. Constipation was significantly more common in buprenorphine users than in control groups. No trials reported on harms of pharmacotherapy in adolescents or in pregnant or postpartum persons.38
None of the 4 trials that reported on harms or adverse events of brief psychosocial interventions identified harms or adverse events. These included 2 trials in college students targeting cannabis use and 2 trials in postpartum persons who received brief interventions after delivery. None of the other psychosocial intervention trials reported on harms or adverse events in adults.38
Response to Public Comment
A draft version of this recommendation statement was posted for public comment on the USPSTF website from August 13 to September 9, 2019. In response to public comments, the USPSTF clarified that “screening” means asking questions about unhealthy drug use (not testing biological specimens, such as blood or urine testing) and that the term “unhealthy drug use” is used to describe nonmedical use of prescription or nonprescription drugs, illegal drugs, or unregulated substances (other than alcohol or tobacco). A few comments requested more information about the USPSTF’s interpretation of the evidence. The USPSTF clarified in the Rationale section that screening in primary care settings for drug use can detect a spectrum of drug use and types of drug use. The USPSTF, therefore, considered evidence from treatment trials that may have included patients with more severe drug use disorders to be applicable to screening. Some comments noted that screening adults may have unintended harms, such as discouraging health care seeking in persons who do not want to be screened, medical and sociolegal consequences of reporting positive screening results, privacy issues, or diverting clinicians’ attention from patients with established drug use disorders. The USPSTF recognizes these as potential harms and provided more details on screening implementation considerations that may address these harms. In addition, the USPSTF clarified in the Practice Considerations section that the net benefit assessment for this recommendation does not apply to settings and populations for which treatment is not provided or the result of screening is punitive.
Some respondents commented that screening should be offered to adolescents, but the USPSTF did not find sufficient evidence to support routine screening in this age group.
The USPSTF identified important gaps related to screening for unhealthy drug use. To fill these gaps, the USPSTF needs more evidence from well-designed studies that further evaluate the following.
- The effectiveness of screening and interventions for drug use in adolescents
- The optimal screening interval for detecting unhealthy drug use
- The accuracy of screening tools for detecting nonmedical use of prescription drugs, including opioids
- Strategies to improve access to pharmacotherapy and psychosocial interventions for persons with various types of drug use disorders
- The harms that occur when the result of screening is punitive
- The benefits and harms of providing prophylactic prescriptions for naloxone “rescue therapy” to patients in whom opioid misuse or opioid use disorders are detected after primary care screening
Several organizations have issued statements about screening for drug use by asking about drug use; these recommendations vary by patient subpopulation. SAMHSA recommends universal screening for substance use (including alcohol), brief intervention, and/or referral to treatment (known as SBIRT) as part of routine health care,12 including during pregnancy.17 The US Departments of Defense and Veterans Affairs39 and the American Academy of Family Physicians40 have adopted the 2008 USPSTF recommendation statement (I statement) indicating that evidence is insufficient to recommend routine screening for illicit drug use. The American Academy of Pediatrics recommends screening adolescents through their early 20s for substance use (including tobacco and alcohol) at every annual physical examination as well as screening adolescents who present to emergency departments or urgent care centers; report cigarette smoking; have depression, anxiety, or other mental health conditions associated with substance abuse; or exhibit school, legal, or social problems or other behavioral changes.41 It provides a list of screening tools that have been validated for use in adolescents through their early 20s.22 The Bright Futures initiative includes a recommendation that all adolescents (including those aged 18 to 21 years) should be screened for substance use (including tobacco and alcohol) as part of an overall psychosocial history.42 The American College of Obstetricians and Gynecologists specifically advises screening women annually for nonmedical use of prescription drugs. It also recommends screening women aged 18 to 26 years for drug use as part of preventive care, universal screening of women before pregnancy and early in pregnancy, and screening postpartum women as indicated.43-49
The US Preventive Services Task Force (USPSTF) members include the following individuals: Alex H. Krist, MD, MPH (Fairfax Family Practice Residency, Fairfax, Virginia, and Virginia Commonwealth University, Richmond); Karina W. Davidson, PhD, MASc (Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York); Carol M. Mangione, MD, MSPH (University of California, Los Angeles); Michael J. Barry, MD (Harvard Medical School, Boston, Massachusetts); Michael Cabana, MD, MA, MPH (University of California, San Francisco); Aaron B. Caughey, MD, PhD (Oregon Health & Science University, Portland); Susan J. Curry, PhD (University of Iowa, Iowa City); Katrina Donahue, MD, MPH (University of North Carolina at Chapel Hill); Chyke A. Doubeni, MD, MPH (Mayo Clinic, Rochester, MN); John W. Epling Jr, MD, MSEd (Virginia Tech Carilion School of Medicine, Roanoke); Martha Kubik, PhD, RN (Temple University, Philadelphia, Pennsylvania); Gbenga Ogedegbe, MD, MPH (New York University, New York, New York); Lori Pbert, PhD (University of Massachusetts Medical School, Worcester); Michael Silverstein, MD, MPH (Boston University, Boston, Massachusetts); Melissa A. Simon, MD, MPH (Northwestern University, Evanston, Illinois); Chien-Wen Tseng, MD, MPH, MSEE (University of Hawaii, Honolulu); John B. Wong, MD (Tufts University School of Medicine, Boston, Massachusetts).
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/conflict-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings. Dr Barry reported receiving grants and personal fees from Healthwise.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Information: The USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
Copyright Notice: USPSTF recommendations are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient's needs. To encourage widespread discussion, consideration, adoption, and implementation of USPSTF recommendations, AHRQ permits members of the public to reproduce, redistribute, publicly display, and incorporate USPSTF work into other materials provided that it is reproduced without any changes to the work of portions thereof, except as permitted as fair use under the US Copyright Act.
AHRQ and the US Department of Health and Human Services cannot endorse, or appear to endorse, derivative or excerpted materials, and they cannot be held liable for the content or use of adapted products that are incorporated on other Web sites. Any adaptations of these electronic documents and resources must include a disclaimer to this effect. Advertising or implied endorsement for any commercial products or services is strictly prohibited.
This work may not be reproduced, reprinted, or redistributed for a fee, nor may the work be sold for profit or incorporated into a profit-making venture without the express written permission of AHRQ. This work is subject to the restrictions of Section 1140 of the Social Security Act, 42 U.S.C. §320b-10. When parts of a recommendation statement are used or quoted, the USPSTF Web page should be cited as the source.
1. Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. Published 2019. Accessed April 22, 2020. https://store.samhsa.gov/product/Key-Substance-Use-and-Mental-Health-Indicators-in-the-United-States-Results-from-the-2018-National-Survey-on-Drug-Use-and-Health/PEP19-5068
2. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987-1012.
3. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448-457.
4. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419-1427.
5. Commonly Abused Drugs Charts. National Institute on Drug Abuse. Published 2018. Accessed April 22, 2020. https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts.
6. Forray A, Foster D. Substance use in the perinatal period. Curr Psychiatry Rep. 2015;17(11):91.
7. Horgan CM. Substance Abuse: The Nation's Number One Health Problem. Robert Wood Johnson Foundation; 2001.
8. Procedure Manual. US Preventive Services Task Force. Published December 2015. Accessed April 22, 2020. https://www.uspreventiveservicestaskforce.org/uspstf/procedure-manual.
9. Harrington M, Robinson J, Bolton S, Sareen J, Bolton J. A longitudinal study of risk factors for incident drug use in adults: findings from a representative sample of the US population. Can J Psychiatry. 2011;56(11):686-695.
10. Substance Abuse and Mental Health Services Administration. Preventing Prescription Drug Misuse: Understanding Who Is at Risk. Michigan.gov. Published 2016. Accessed April 22, 2020. https://www.michigan.gov/documents/mdhhs/UnderstandingWhoIsAtRisk_547024_7.pdf
11. Cook JL, Green CR, de la Ronde S, et al. Epidemiology and effects of substance in pregnancy. J Obstet Gynaecol Can. 2017;39(10):906-915.
12. Patnode CD, Perdue LA, Rushkin M, O’Connor EA. Screening for Drug Use in Primary Care in Adolescents and Adults, Including Pregnant Women: An Updated Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 186. Agency for Healthcare Research and Quality; 2020. AHRQ publication 19-05255-EF-1.
13. Principles of Substance Use Disorder Treatment in Adolescents: A Research-Based Guide. National Institute on Drug Abuse. Published 2014. Accessed April 22, 2020. https://www.drugabuse.gov/publications/principles-adolescent-substance-use-disorder-treatment-research-based-guide/principles-adolescent-substance-use-disorder-treatment
14. Medications to Treat Opioid Disorder. National Institute on Drug Abuse. Published 2018. Accessed April 22, 2020. https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview.
15. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. Substance Abuse and Mental Health Services Administration. Published 2018. Accessed June 26, 2019. https://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054.
16. Treating Opioid Use Disorder During Pregnancy. National Institute on Drug Abuse. Published 2017. Accessed June 26, 2019. https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy.
17. Substance Abuse and Mental Health Services Administration. A Guide to Substance Abuse Services for Primary Care Clinicians. National Center for Biotechnology Information. Published 1997. Accessed April 22, 2020. https://www.ncbi.nlm.nih.gov/books/NBK64827/.
18. Principles of Drug Addiction Treatment. A Research-Based Guide (Third Edition). National Institute on Drug Abuse. Published 2018. Accessed April 22, 2020. https://www.drugabuse.gov/publications/principles-drug-addiction-treatment/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies
19. American College of Obstetricians and Gynecologists. Committee Opinion No. 633: alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2015;125(6):1529-1537.
20. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. AGOG Committee Opinion No. 473: substance abuse reporting and pregnancy. Obstet Gynecol. 2011;117(1):200-201.
21. Laws on Confidentiality Healthcare. Society for Adolescent Health and Medicine. Published 2019. Accessed April 22, 2020. https://www.adolescenthealth.org/Resources/Clinical-Care-Resources/Confidentiality/Confidentiality/Laws-on-Confidentiality-Healthcare.aspx
22. Levy SJ, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1). pii: e20161211.
23. Substance Use During Pregnancy. Guttmacher Institute. Published April 1, 2020. Accessed April 22, 2020. https://www.guttmacher.org/print/state-policy/explore/substance-use-during-pregnancy
24. Miranda L, Dixon V, Reyes C. How States Handle Drug Use During Pregnancy. ProPublica. Published September 30, 2015. Accessed April 22, 2020. https://projects.propublica.org/graphics/maternity-drug-policies-by-state
25. Effective Health Care Program. Interventions for Substance Use Disorders in Adolescents: A Systematic Review. Research Protocol. Agency for Healthcare Research and Quality; 2018.
26. National Institute on Drug Abuse. Drugs, Brains, and Behavior: The Science of Addiction. National Institute on Drug Abuse; 2014.
27. Sharma A, Morrow JD. Neurobiology of adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):367-375.
28. Hammond CJ. The role of pharmacotherapy in the treatment of adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(4):685-711.
29. Moyer VA; US Preventive Services Task Force. Primary care behavioral interventions to reduce illicit drug and nonmedical pharmaceutical use in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(9):634-639.
30. Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(18):1899-1909.
31. Siu AL; US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(8):622-34.
32. Moyer VA; US Preventive Services Task Force. Primary care interventions to prevent tobacco use in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(8):552-7.
33. Siu AL, Bibbins-Domingo K, Grossman DC, et al; US Preventive Services Task Force. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(4):380-387.
34. Siu AL; US Preventive Services Task Force. Screening for depression in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(5):360-366.
35. LeFevre ML; US Preventive Services Task Force. Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(10):719-726.
36. Screening for Illicit Drug Use: U.S. Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force. Published 2008. Accessed April 22, 2020. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening
37. Patnode CD, Perdue LA, Rushkin M, et al. Screening for unhealthy drug use: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. Published June 9, 2020.
38. Chou R, Dana T, Blazina I, Grusing S, Bougatsos C. Interventions for Drug Use—Supplemental Report: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 187. Agency for Healthcare Research and Quality; 2020. AHRQ publication 19-05255-EF-2.
39. Department of Veteran Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. US Department of Veterans Affairs. Published 2015. Accessed April 22, 2020. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf.
40. Clinical Preventive Service Recommendation: Illicit Drug Use. American Academy of Family Physicians. Published 2018. Accessed April 22, 2020. https://www.aafp.org/patient-care/clinical-recommendations/all/illicit-drug-use.html.
41. Substance Use Screening and Intervention Implementation Guide. American Academy of Pediatrics. Accessed April 22, 2020. https://www.aap.org/en-us/Documents/substance_use_screening_implementation.pdf.
42. Hagan JF, Shaw JS, Duncan P, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 4th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2017.
43. ACOG Committee Opinion No. 598: Committee on Adolescent Health Care: the initial reproductive health visit. Obstet Gynecol. 2014;123:1143-1147.
44. ACOG Committee Opinion No. 762: prepregnancy counseling. Obstet Gynecol. 2019;133:e78-e89.
45. Obstetric Care Consensus No. 8: interpregnancy care. Obstet Gynecol. 2019;133:e51-e72.
46. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 479: methamphetamine abuse in women of reproductive age. Obstet Gynecol. 2011;117(3):751-755.
47. Committee on Obstetric Practice. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.
48. American College of Obstetricians and Gynecologists. Committee Opinion No. 722: Marijuana use during pregnancy and lactation. Obstet Gynecol. 2018;131(1):164.
49. McKinney J, Keyser L, Clinton S, Pagliano C. ACOG Committee Opinion No. 736: optimizing postpartum care. Obstet Gynecol. 2018;132(3):784-785.
|Rationale||Adults 18 y and older||Adolescents aged 12 to 17 y|
|Detection||Adequate evidence that available screening tools can detect a spectrum of drug use and types of drug use||Inadequate evidence that available screening tools can detect most types of unhealthy drug use|
|Benefits of early detection and intervention and treatment||
|Harms of early detection and intervention and treatment||
Abbreviations: FDA, US Food and Drug Administration; USPSTF, US Preventive Services Task Force.
National Institute on Drug Abuse
Screening and Assessment Tools Chart
Screening for Drug Use in General Medical Settings: A Resource Guide for Providers
Substance Abuse and Mental Health Administration (SAMHSA)
Finding Quality Treatment for Substance Use Disorders.
Substance Abuse Confidentiality Regulations
SAMHSA–Health Resources and Services Administration Center for Integrated Health Solutions
Substance Use Disorder and Pregnancy
SAMHSA Center for Substance Abuse Treatment
A Guide to Substance Abuse Services for Primary Care Clinicians